Servier (PRIVATE.SERVIER)

Overall impact
B (77)

Commentary

Servier is a strong overall performer. With a 'B' rating of 76.7 for overall impact (91st percentile compared to all companies), Servier ranks 20th out of 154 industry peers, behind Benitec Biopharma, Eisai, Astellas Pharma and 16 others, and ahead of Adamis Pharmaceuticals, Aquinox Pharmaceuticals, Assertio Therapeutics and 131 others. On top material causes for Servier's industry (Pharmaceuticals & Biotech), Servier performs well in Disease Eradication (96.3 score), Fair Labor Practices (95.2), Reduced Inequality (86.0) and 3 other causes where it received an 'A' score and performs poorly in Accountable Institutions (37.4 score).
Impact
Cause PRIVATE.SERVIER
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1954
Employees
21,900
Sector
Health Care
Industry
Pharmaceuticals
Sub-industry
Pharmaceuticals
SASB industry
Biotechnology & Pharmaceuticals
Headquarters
Suresnes, France
Share classes
PRIVATE.SERVIER
Description
Operator of a pharmaceutical company intended to play a vital role in advancing medical science, improving patient outcomes, and addressing global healthcare challenges. The company researches, develops, and produces drugs for oncology, cardiology, metabolic, central nervous system, psychiatric, bone, muscle, and joint diseases, enabling doctors to prescribe generic drugs with minimal side effects for low-cost treatments.
Material causes
Ethos considers the following causes material for Servier, based on its industry sub-industry Pharmaceuticals. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.